Compare LCNB & MDXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | LCNB | MDXH |
|---|---|---|
| Founded | 1877 | 2003 |
| Country | United States | Belgium |
| Employees | N/A | N/A |
| Industry | Major Banks | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 205.5M | 167.8M |
| IPO Year | N/A | 2021 |
| Metric | LCNB | MDXH |
|---|---|---|
| Price | $16.34 | $3.66 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $7.67 |
| AVG Volume (30 Days) | 25.0K | ★ 124.4K |
| Earning Date | 01-29-2026 | 02-26-2026 |
| Dividend Yield | ★ 5.38% | N/A |
| EPS Growth | ★ 220.73 | N/A |
| EPS | ★ 1.67 | N/A |
| Revenue | $89,312,000.00 | ★ $103,069,000.00 |
| Revenue This Year | $18.04 | $23.34 |
| Revenue Next Year | $4.36 | $22.98 |
| P/E Ratio | $9.81 | ★ N/A |
| Revenue Growth | 19.58 | ★ 21.68 |
| 52 Week Low | $13.34 | $1.35 |
| 52 Week High | $17.84 | $5.33 |
| Indicator | LCNB | MDXH |
|---|---|---|
| Relative Strength Index (RSI) | 51.79 | 57.67 |
| Support Level | $16.14 | $3.00 |
| Resistance Level | $16.74 | $3.43 |
| Average True Range (ATR) | 0.37 | 0.22 |
| MACD | -0.05 | 0.05 |
| Stochastic Oscillator | 56.76 | 87.84 |
LCNB Corp operates within the financial sector in the United States. As the holding company of the National Bank, it conducts the business of providing commercial and personal banking services. Its suite of banking products includes commercial and industrial loans, consumer loans, safe deposit boxes, night depositories, cashier's checks, utility bill collections and notary public service. Besides, it provides the avenue of United States Treasury notes, the United States agency notes, certificates of deposit, and equity securities.
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.